(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/093422 A2

(51) International Patent Classification[7]: C12N

(21) International Application Number: PCT/US03/13521

(22) International Filing Date: 30 April 2003 (30.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/376,566 1 May 2002 (01.05.2002) US

(71) Applicant *(for all designated States except US)*: **SCHERING AKTIENGESELLSCHAFT** [DE/DE]; D-13342 BERLIN (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LIGHT, David** [US/US]; 614 South Freemont Street, San Mateo, CA 94402 (US). **MCLEAN, Kirk** [US/US]; 291 Capricorn Avenue, Oakland, CA 94611 (US).

(74) Agents: **ZELANO, Anthony, J.** et al.; Millen, White, Zelano & Branigan, P.C., Arlington Courthouse Plaza 1, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA 22201 (US).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

[Continued on next page]

(54) Title: NOVEL TISSUE FACTOR TARGETED ANTIBODIES AS ANTICOAGULANTS



(57) Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

WO 03/093422 A2

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.